CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
VAY736 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02149420
NCT02149420Phase 2Completed
CompareCT.gov

A Single Dose, Double-blind, Placebo-controlled, Parallel Study to Assess the Pharmacodynamics, Pharmacokinetics and Safety and Tolerability of VAY736 in Patients With Primary Sjögren's Syndrome

Novartis Pharmaceuticals·interventional·Posted May 29, 2014·Updated Oct 4, 2021

In Brief

A Phase 2 clinical trial evaluating VAY736 and Placebo for Primary Sjögren's Syndrome. Completed, enrolled 27 participants across 1 site.

Detailed Summary

This study was designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of a single intravenous infusion of VAY7346 monoclonal antibody in pSS patients

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Sjögren's Syndrome
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 29, 2014
Enrollment StartMay 23, 2014
Primary CompletionFeb 7, 2018
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 12.1 years ago

Interventions

VAY736drug

Placebodrug